## 5 Conclusions
\begin{tabular}{c c c c c c c c} \hline \hline \multicolumn{4}{c}{**Kellgren/Lawrence Scoring System**} & \multicolumn{4}{c}{**Nottingham Scoring System**} \\ \hline
**Parameter** & \multicolumn{2}{c}{**Median (1 st-3 rd Quantiles)**} & \multicolumn{2}{c}{_p-Value of_**} & \multicolumn{2}{c}{_p-Value of_**} & \multicolumn{2}{c}{**Median (1 st-3 rd Quantiles)**} & \multicolumn{2}{c}{_p-Value of_**} \\ \cline{3-8}  & **Grade 2** & **Grade 3** & **Grade 4** & **Test** & **Wilcoxon** & **Grade 2** & **Grade 3** & **Test** \\ \hline uC2C/Crea, ng/mmol & 610 (526–747) & 753 (627–986) & 1062 (677–1301) & 0.054 & 0.047 & 732 (635–967) & 934 (623–1179) & 0.27 \\ \hline KOOSymp & 44 (39–50) & 26 (17–40) & 29 (21–40) & 0.20 & 0.57 & 30 (22–46) & 29 (17–40) & 0.30 \\ \hline KOOSpain & 46 (38–50) & 34 (25–44) & 33 (27–42) & 0.37 & 0.95 & 40 (31–47) & 33 (24–42) & 0.09 \\ \hline KOOSadl & 39 (33–44) & 35 (29–44) & 38 (28–45) & 0.79 & 0.53 & 36 (31–43) & 35 (28–44) & 0.81 \\ \hline KOOSp/recr & 0 (0–1) & 0 (0–0) & 0 (0–4) & 0.24 & 0.10 & 0 (0–0) & 0 (0–4) & 0.18 \\ \hline KOOSqol & 20 (13–30) & 15 (5–20) & 15 (5–20) & 0.57 & 0.78 & 18 (5–25) & 15 (5–20) & 0.61 \\ \hline \hline \end{tabular}   
* The Knee Injury and Osteoarthritis Outcome Score (KOOSymp) subscales: symptoms (KOOSymp), pain (KOOSpain), activities of daily living (KOOSadl), sport and recreation (KOOSsp/recr), and knee-related quality of life (KOOSqol). \begin{table}
\begin{tabular}{c c c} \hline \hline
**Radiographic kOA Grades** & **gOA** \\ \hline KL & Grade 2 & Grade 3 \\ \hline Grade 2 & 3 & 1 \\ \hline Grade 3 & 11 & 28 \\ \hline Grade 4 & 2 & 41 \\ \hline \hline \end{tabular}  
* KL—the severity grade of knee OA assessed by the Kellgren–Lawrence system; gOA—the highest grade of knee OA changes in two knee joint compartments (tibiofemoral and/or patellofemoral joints) assessed by the Nottingham system (NSy).  
\end{table} 
Table 1: Distribution of radiographic grades of kOA evaluated by two different systems: KL and NSy. \begin{table}
\begin{tabular}{c c c c c c c c} \hline \hline \multicolumn{2}{c}{**KOOS Subscales**} & \multicolumn{2}{c}{**Whole Group**} & \multicolumn{2}{c}{**Females**} & \multicolumn{2}{c}{**Males**} \\ \hline \multicolumn{2}{c}{} & \multicolumn{2}{c}{**Spearman’s Rho**} & \multicolumn{2}{c}{**_p-Value_**} & \multicolumn{2}{c}{**Spearman’s Rho**} & \multicolumn{2}{c}{**_p-Value_**} & \multicolumn{2}{c}{**Spearman’s Rho**} & \multicolumn{2}{c}{_p-Value_**} \\ \hline KOOSsymp & -0.13 & 0.25 & -0.23 & 0.15 & 0.07 & 0.66 \\ \hline KOOSpain & -0.31 & 0.006 & -0.20 & 0.21 & -0.33 & 0.04 \\ \hline KOOSadl & -0.20 & 0.08 & -0.12 & 0.45 & -0.20 & 0.22 \\ \hline KOOSp/recr & -0.11 & 0.32 & -0.03 & 0.87 & -0.14 & 0.40 \\ \hline KOOSqol & -0.10 & 0.37 & -0.06 & 0.72 & -0.05 & 0.77 \\ \hline SF36 PF & -0.13 & 0.26 & -0.24 & 0.14 & -0.02 & 0.91 \\ \hline SF36 RP & 0.08 & 0.49 & -0.14 & 0.40 & 0.22 & 0.17 \\ SF36 RE & -0.16 & 0.16 & -0.24 & 0.14 & -0.05 & 0.76 \\ \hline SF36 VT & -0.23 & 0.05 & -0.22 & 0.19 & -0.16 & 0.31 \\ \hline SF36 MH & -0.12 & 0.28 & 0.11 & 0.50 & -0.24 & 0.13 \\ \hline SF36 SF & -0.24 & 0.03 & -0.38 & 0.02 & -0.08 & 0.64 \\ \hline SF36 BP & -0.18 & 0.11 & 0.18 & 0.28 & -0.12 & 0.45 \\ \hline SF36 CH & 0.02 & 0.85 & 0.12 & 0.46 & 0.01 & 0.95 \\ \hline TUG & 0.16 & 0.17 & 0.16 & 0.32 & 0.10 & 0.54 \\ \hline Test-Chair & -0.20 & 0.07 & -0.18 & 0.27 & -0.13 & 0.43 \\ \hline
30 sCST & -0.10 & 0.44 & -0.08 & 0.65 & 0.07 & 0.73 \\ \hline
30 mFPWT & 0.12 & 0.30 & 0.14 & 0.40 & -0.01 & 0.94 \\ \hline \hline \end{tabular}
\end{table} 
Table 10: Correlations between uC2C and results of subjective complaints or objective functional tests before TKR.